• Primary mesencephalic neuron cultures with immature astrocytes able to specifically kill dopaminergic neurons in different medium
  • Primary mesencephalic neuron cultures with / without astrocytes
    Treatment with MPP+, rotenone
  • Primary mesencephalic neuron cultures with / without microglial cells
    Compounds with potential anti-inflammatory activities could be tested (several treatments possible depending on the pathway of interest)
  • Primary cell cultures of cortical, striatal and dopaminergic neurons infected with virus vectors containing aggregated a-synuclein
READ-OUT

Cell survival, cell proliferation, morphological changes, protein measurement, etc.

cell survival, cytokine measurement, cell proliferation, morphological changes, protein density

cell survival, aggregation

 

  • MPTP mouse and 6-OHDA mouse/rat
  • Transgenic models of alpha-synuclein mice, KO Parkin, LRRK2 G2019S mice
  • Nigrostriatal synucleinopathy: viral vector-mediated models (CAV2- mice, AAV-rats) coding for alpha-synuclein (WT or A53T)
  • A “double hit” rat model: co-expression of alpha-synuclein and C-Terminal domain of LRRK2-G2019S (increase of alpha-synuclein toxicity).
READ-OUT

Behavioral changes, stereological cell count in the substantia nigra (TH-positive neurons), number of alpha-synuclein aggregates, partial loss of dopaminergic fibers/DAT binding sites using microPET radiotracers, etc.

 

  • MPTP-lesion model in squirrel monkey, macaque or baboons
  • Nigrostriatal synucleinopathy: viral vector-mediated models (CAV2, AAV) coding for alpha-synuclein (WT or A53T)
READ-OUT Behavioral changes, stereological cell count in the substantia nigra (TH-positive neurons), number of alpha-synuclein aggregates, partial loss of dopaminergic fibers/DAT binding sites using microPET radiotracers, etc.

 

  • Clinical investigation Center for biotherapies, Biological resource center, stratified cohorts of patients
READ-OUT PET, SPECT and MRI imaging, Markers of dopaminergic system and neuroinflammation, platforms of movement analysis, Neurophysiology, abnormal movement recordings, transcranial magnetic stimulation, etc.

 

> For a complete panorama of our offer regarding Parkinson’s disease, click here.